Source-grounded facts extracted from RESMED INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
RESMED INC reported the quarter ended March 31, 2026 results: revenue $1,431.4, net income $398.7, EPS $2.74.
“Results and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended March 31, 2026 March 31, 2025 % Change Constant Currency (A) Revenue $ 1,431.4 $ 1,291.7 11 % 8 % Gross margin 62.2 % 59.3 % 5 Non-GAAP gross margin (B) 62.8 % 59.9 % 5 Selling, general, and administrative expenses 285.7 245.3 16 11 Non-GAAP selling,”
Aaron Bloomer was appointed as Chief Financial Officer at RESMED INC.
“On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.”
Brett Sandercock departed as Chief Financial Officer at RESMED INC.
“On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.”
Christopher DelOrefice was appointed as Director at RESMED INC.
“On August 15, 2024, ResMed Inc. appointed Christopher DelOrefice to serve on its board of directors, with a term expiring at ResMed’s 2024 annual meeting of stockholders on November 21, 2024”
RESMED INC reported the quarter ended March 31, 2024 results: revenue $1.2 billion, EPS $2.04.
“he prior year period • Revenue increased by 7% to $1.2 billion; up 7% on a constant currency basis • Gross margin grew 260 bps to 57.9%; non-GAAP gross margin grew”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.